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ABSTRACT
Background and Objectives: Hepatitis C virus (HCV) infection is a major public health issue. 
There is substandard uptake in HCV assessment and treatment among people who inject drugs 
(PWID). Community fibroscanning is used to assess disease severity and target treatment. 
Methods: A survey was administered to a cohort of chronically HCV infected patients attending 
a community fibroscanning clinic. Questions targeted diagnosis of HCV, suitability, willingness 
and barriers to engagement in treatment. Descriptive and regression analysis, with thematic 
analysis of open-ended data was conducted. Results: There was high acceptance of community 
fibroscanning among this cohort with over 90% (68) attending. High levels of unemployment 
(90%) and homelessness (40%) were identified. Most patients were on methadone treatment 
and had been HCV infected for greater than 10 years with length of time since HCV diagnosis 
being significantly longer in patients with fibroscan scores > 8.5 kPa (P = 0.016). With each unit 
increase in methadone dose, the odds of the >8.5 fibroscan group increased by 5.2%. Patient 
identified barriers to engagement were alcohol and drug use, fear of HCV treatment and liver 
biopsy, imprisonment, distance to hospital and early morning appointments. Conclusion: The 
study highlights the usefulness of community fibroscanning. Identifying barriers to treatment in 
this cohort affords an opportunity to increase the treatment uptake. The availability of afternoon 
clinics and enhanced prison linkage are warranted.
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INTRODUCTION 
Hepatitis C virus (HCV) infection remains 
a major public health burden. It is spread 
by contact with infected blood or other 
bodily fluids.[1-6] An estimated 185 million 
people are infected with HCV globally[7] 
with a reported 15 million Europeans living 
with HCV infection.[8, 9] Chronic disease 
outcomes occur in 55-85% of  untreated 
cases, and center around an impaired 
quality of  life, liver cirrhosis, liver failure 
and hepatocellular carcinoma.[10, 11] Injecting 
drug use remains a significant driver of  the 
European HCV epidemic with estimates 
that HCV antibody prevalence among 
persons who inject drugs (PWID) in 29 
European countries ranges from 5% to 90% 
with growing rates of  HCV among new 
injectors of  novel psychoactive substances 
(NPS).[8,12-13] 
There is a high prevalence of  HCV within 
the aging PWID population, characterized 
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by many undiagnosed cases and failure to access 
treatment [14] Surveillance and monitoring of  HCV in 
Europe, particularly regarding levels of  antiviral treatment 
uptake among PWID are limited.[15-17] Recent increases in 
HCV infection among PWID in some European countries 
are reported despite increased efforts to upscale the HCV 
cascade of  care.[18,19]
Low rates of  HCV treatment uptake and sub-optimal 
access are reported among PWID.[6, 9, 20-22] PWID encounter 
significant barriers to accessing the HCV treatment[15,23] and 
are often denied treatment due to concerns around the 
on-going risk behavior despite treatment reducing further 
transmission.[6, 23, 24] HCV treatment outcomes in PWID 
are comparable to general population patients with no 
history of  drug use.[23,25-27] Despite suboptimal access and 
uptake, research demonstrates a PWID interest in HCV 
treatment.[28-32]
Up to recently, the standard treatment for chronic HCV 
infection was pegylated interferon (PEG-IFN) and ribavirin 
(RBV).[33] The development of  new drug therapies includes 
protease and polymerase inhibitors (DAAs) that are well 
tolerated, do not require liver biopsy and have minimal side 
effects. Liver biopsy whilst evident as the gold standard of  
liver fibrosis is difficult, invasive and costly.[34] Liver stiffness 
measurement (LSM) using fibroscan is increasingly being 
used to assess disease severity.[35] This procedure can help 
to enhance HCV assessment, reduce treatment barriers, 
triage patients and target therapy.[14, 36] Several studies 
have reported on the feasibility of  fibroscanning as a 
screening tool for drug users, with high rates of  acceptance 
and uptake within various treatment and street outreach 
settings.[37-41]
In Ireland, an estimated 20,000-50,000 people have been 
exposed to HCV infection, giving a prevalence rate of  
1-2%.[42] Most recent prevalence data of  HCV in the Irish 
PWID population ranges from 62-81%[42, 43] with risk 
factors similar to those reported elsewhere. These are 
injecting drug use,[42, 43-47] frequency and length of  time 
injecting,[45, 48, 49] needle sharing and having a history of  
imprisonment.[45] Low uptake of  screening and follow up 
assessments are also reported.[51-53] In Ireland, the treatment 
with DAAs is restricted to those with more advanced 
liver disease, determined by fibroscan score, with current 
guidelines identifying those with scores of  > 8.5 kPa as 
being eligible for the treatment. 
METHODS
The aim of  the study was to report on characteristics of  
OST patients attending a community based fibroscanning 
clinic, and their reported barriers to engaging with HVC 
treatment in Ireland. The fibroscanning clinic took place 
in The City Clinic, the largest community based drug 
treatment center in Ireland. This center provides OST to 
300 opioid dependent patients living in the North inner 
city area of  Dublin, an area of  social deprivation. Patients 
entering OST are offered viral screening within a month of  
starting the treatment and post a risk behavior thereafter. 
A viral screen audit was completed to identify patients 
with chronic HCV infection, who had not successfully 
completed the HCV treatment in the past and who would 
benefit from an assessment by fibroscan (n=80).  
The data collection tool was designed based on consultation 
with the literature and team review. The instrument 
contained a series of  descriptive questions collecting data 
on gender, age, employment status, dose and length of  
time on methadone, length of  time since/location of  HCV 
diagnosis, if  referred/attended hospital for follow up, if  
ever had a biopsy and if  previously offered / completed 
HCV treatment. Patients were asked a series of  open 
ended questions around HCV symptoms experienced, 
self-reported drug and alcohol stability, reasons for non-
attendance, factors contributing to non-attendance and 
potential facilitators for treatment engagement. 
Ethical approval was given by The Mater Hospital, Dublin, 
Ireland as part of  the European HepCare Project.  Patients 
were given an information sheet on the study and provided 
written consent.  The questionnaire was administered by 
a research assistant who accompanied the nurse specialist 
performing the fibroscan. 
Anonymized data yielded descriptive statistics (frequencies, 
percentages) to summarize the participant characteristics. 
Statistical tests using SPSS including the Chi square tests, 
t-tests and P-values were used to assess the differences in 
categorical data, with a significance level of  0.05. Multi-
nominal logistic regression analysis was used to determine 
predictors of  answer responses with the neutral response 
category as the reference. Qualitative open ended comment 
data were thematically coded for common and emergent 
themes using QSR –NVIVO-10.  
RESULTS
Participant profile
The mean age of  the participants was 39 years with no 
significant difference between men and women. A high 
proportion of  patients described their accommodation as 
not stable (40%) and only 9% were engaged in some form 
of  employment. The average methadone dose was 75 mL 
with an average of  10 years on MMT (Table 1) with again 
no difference between men and women. The majority of  
participants (71%) self-declared ongoing/drug or alcohol 
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instability as a factor impacting their ability to engage with 
the HCV assessment and treatment. 
On an average, the study population was diagnosed with 
Hepatitis C for 10.5 years, with just less than half  (47%) 
describing having symptoms related to HCV infection. 
Over half  the group (57%) had previously been offered 
a hospital appointment for HCV follow-up with most 
attending (54%). Less than a third (27%) of  the group had 
a previous liver biopsy or fibroscan. Of  this group, only 
thirteen patients had been assessed as suitable for treatment 
with significantly more men than women being told they 
were suitable for interferon based treatment (26% vs. 0%; 
P=0.016) (Table 2), but none of  these had been engaged. 
Fibro scanning results (Tables 3 and 4)
The average Fibro scan score was 6.4 kPa. Almost a 
third of  this cohort had Fibro scan sore > 8.5 kPa, with 
a slightly higher proportion of  men (38%) compared to 
women (16.6%) reaching this score but this failed to reach 
statistical significance (P=0.072). Over 20% of  patients had 
a fibroscan score of  > 12.5 kPa. Importantly, there was no 
significant difference between patients experiencing self-
declared HCV related symptoms and their fibroscan score 
[> 8.5 (P=0.5) (Table 3), > 12.5 kPa (P=0.2) (Table 4)]. 
Participants with a Fibro scan score > 8.5 kPa were 
diagnosed with having Hepatitis C for a significantly longer 
period than those with a san score < 8.5 kPa (15 years vs. 
10 years, P = 0.016, Table 3). Homelessness, employment 
status, length of  time on MMT, patients experiencing 
HCV related symptoms and self-declared drug and alcohol 
Table 1: Population characteristics by gender
 Total (n=68) Male (n= 50) Female (n= 18) P-Value
Age (years) 39.0 (35.2, 44.0) 40.0 (35.0, 45.0) 39.0 (35.7, 42.0) 0.882
Accommodation status stable % (n) 61.7 (42) 58.0 (29) 72.2 (13) 0.366
Engaged in work % (n) 8.8 (6) 6.0 (3) 16.6 (3) 0.201
Time on MMT (years) 10.0 (5.0, 19.5) 10.0 (5.0, 19.2) 12.5 (6.2, 19.5) 0.773
Methadone dose (mL) 75.0 (47.0, 90.0) 75.0 (50.0, 90.0) 70.0 (43.7, 90.0) 0.251
Alcohol /drug unstable (self-declared) % (n) 70.5 (48) 70.0 (35) 72.2 (13) 0.913
Values are median (25th–75th percentile) or % (n). Continuous variables assessed by independent T-test; Categorical variables assessed by Chi-square 
analysis. MMT: methadone maintenance treatment. P<0.05 were considered statistically significant.
Table 2: Population characteristics by HCV issues and gender
 Total (n=68) Male (n= 50) Female (n=18) P-Value
Diagnosed hepatitis C (years) 10.5 (8.0, 16.2) 10.0 (7.7, 17.0) 12.5 (9.0, 6.7) 0.817
Symptoms related to hepatitis C % (n) 47.0 (32) 42.0 (21) 61.1 (11) 0.172
Offered OPD appointment % (n) 57.3 (39) 60.0 (30) 50.0 (9) 0.414
Attend OPD appointment % (n) 54.4 (37) 54.0 (27) 55.5 (10) 0.906
Previous liver biopsy or Fibroscan % (n) 29.4 (20) 32.0 (16) 22.2 (4) 0.348
Fibroscan result (kPa) 6.4 (5.2, 10.1) 7.2 (5.3, 11.8) 5.6 (5.2, 6.7) 0.104
Previously assessed suitable for treatment % (n) 19.1 (13) 26.0 (13) 0 0.016
Fibroscan result >8.55 (kPa) % (n) 32.3 (22) 38.0 (19) 16.6 (3) 0.072
Fibroscan result >12.5 (kPa) % (n) 20.3 (12) 20.0 (10) 11.1 (2) 0.362
Values are median (25th–75th percentile) or % (n). Continuous variables assessed by independent T-test; Categorical variables assessed by Chi-square. HCV: 
hepatitis C virus. P<0.05 were considered statistically significant.
Table 3: Fibro scan score population characteristics (>8.5 kPa)
 Fibro scan score
 <8.5 (n=37) >8.5 (n=22) P-Value
Age (years) 39.0 (35.0, 42.5) 40.0 (36.0, 45.2) 0.339
Accommodation status stable %(n) 64.8 (24) 59.0 (13) 0.404
Engaged in work %(n) 8.1 (3) 9.0 (2) 0.965
Time on MMT (years) 10.0 (5.0, 17.0) 10.0 (2.0, 20.0) 0.921
Methadone dose (mL) 60.0 (40.0, 82.5) 80.0 (63.7, 95.0) 0.072
Diagnosed hepatitis C (years) 10.0 (6.0, 15.0) 15.0 (8.5, 20.0) 0.016
Having symptoms related to hepatitis C (self-declared) % (n) 43.2 (16) 50.0 (11) 0.513
Alcohol /drug unstable (self-declared) % (n) 67.5 (25) 77.2 (17) 0.941
Values are median (25th–75th percentile) or % (n). Continuous variables assessed by independent T-test; Categorical variables assessed by Chi-square 
analysis. MMT: methadone maintenance treatment. P<0.05 were considered statistically significant.
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stability seemed to have no impact on a patient having a 
fibro scan score > 8.5 kPa and being eligible for treatment 
with DAAs in Ireland. Of  particular interest is that with 
each unit increase in methadone dose, the odds of  being 
in the > 8.5 Fibroscan group increased by 5.2 % (Table 5)
Thematic analysis 
HCV symptoms experienced
A majority of  participants (70%) self-reported drug 
instability. Participants reported use of  excess alcohol, 
smoking of  opiates and crack cocaine and use of  
benzodiazepines, with a minority reporting continued 
IDU of  heroin. A minority reported daily or problematic 
use of  alcohol. HCV symptoms experienced included 
abdominal pain, stomach bloating, fatigue, anxiety, weight 
gain, swelling of  the limbs and a yellow tinge to the skin 
(Table 5). Some participants were not aware of  any HCV 
symptoms. A majority of  those with fibroscan scores of  
> 8.5 kPa were not aware of  HCV symptoms other than 
fatigue (Beta = 0.051, Exp (B) = 1.052, P = 0.026, 95% 
CI (1.006-1.1). 
Barriers to attendance 
Individual patient reasons for not initially attending the 
HCV clinic centered around on-going drug and alcohol 
use, on-going injecting drug use, not wanting to have 
treatment at the time, fear around invasive HCV and 
treatment interventions and addiction treatment relapse. 
Many narratives illustrated lack of  readiness for treatment 
of  HCV. One participant described being too ill from 
interferon to attend the clinic. Of  particular note were the 
significant barriers reported by those with a fibroscan score 
of  > 8.5 kPa, which centered on the inability to engage with 
HCV treatment and care due to custodial sentencing, poor 
prison referrals, parental bereavement and chaotic family 
and drug using lifestyles. Many participants also described 
chaotic personal and family lifestyles, and lengthy distance 
from the clinic making treatment adherence and attendance 
at early appointments difficult to commit to.
Enablers to treatment
When questioned about the facilitators to ensure continued 
engagement with HCV treatment, participants described 
structural barriers that included problems when no follow-
up appointments were kept.  This may have been due to 
clinic staff  concern around chaotic lifestyles and on-going 
drug and injecting drug use, or appointments provided and 
not attended. Afternoon appointments, enhanced prison 
referral mechanisms into the community fibroscanning 
unit, and the location of  services within the addiction 
treatment and detoxification services were viewed as 
potentially useful. 
DISCUSSION
The study presented a unique Irish profile of  OST patients 
accessing a community based fibro-scanning clinic in 
Dublin, Ireland. The participants in this study reflect an 
Table 4: Fibro scan score population characteristics (>12.5 kPa)
 Fibro scan score
 <12.5 (n=47) >12.5 (n=12) P-Value
Age (years) 39.0 (35.0, 43.0) 40.5 (36.0, 46.0) 0.301
Accommodation status stable%(n) 59.5 (28) 75.0 (9) 0.584
Engaged in work % (n) 10.6 (5) 0 (0) 0.170
Time on MMT (years) 10.0 (4.2, 15.2) 20.0 (9.2, 25.0) 0.179
Methadone dose (mL) 65.0 (45.0, 80.0) 90.0 (72.5, 98.7) 0.091
Diagnosed hepatitis C (years) 10.0 (7.0, 15.0) 17.0 (14.0, 20.0) 0.012
Having symptoms related to Hepatitis C (self-declared) % (n) 40.4 (19) 66.6 (8) 0.244
Alcohol /drug unstable (self-declared) % (n) 72.3 (34) 66.6 (8) 0.294
Values are median (25th–75th percentile) or % (n). Continuous variables assessed by independent T-test; categorical variables assessed by chi-square 
analysis. MMT: methadone maintenance treatment. P<0.05 were considered statistically significant.
Table 5:  Predictor’s of fibroscan scores
 Unstandardized coefficients 95% Confidence interval
Variable B Std. Error P-value Lower Upper
Age 0.13 0.35 0.717 -0.58 0.83
Gender 3.64 4.06 0.377 -4.63 11.90
Methadone dose (mL) 0.16 0.08 0.049 0.00 0.31
Years diagnosed Hepatitis C (years) 0.21 0.32 0.506 -0.43 0.85
Linear regression analysis
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aging cohort of  PWIDs with a mean age of  39 years, with 
high levels of  unemployment (> 90%) and homelessness 
(40%) on long term MMT (> 10 years) and having a 
diagnosis of  untreated chronic HCV infection for over 
a decade. A majority of  patients (n = 70%) described the 
ongoing issues of  drug and alcohol instability that impacted 
their ability to engage with HCV services. This group was 
traditionally seen as hard to reach group for engagement 
with health services and in particular with HCV screening, 
assessment and treatment.[9,14,21-23] This study shows that 
when screening and fibro scanning are offered at drug 
treatment locations, patients will engage in these services 
(n= 85%).[54] 
The average fibro scan score in this cohort was 6.4 kPa, 
which is similar to that found in other studies.[39,41] Just 
under a third of  participants had scores > 8.5 kPa (30%) 
indicating at least moderate fibrosis and eligible for DAAs 
in accordance with Irish HCV treatment criteria. 20% of  
the cohort had a score > 12.5 kPa, indicative of  cirrhosis. 
Of  interest is that self-declared HCV related symptoms 
were no different in those with normal scores (< 8.5 kPa) 
compared to those with scores indicative of  fibrosis (> 8.5 
kPa) and cirrhosis (> 12.5 kPa). This is an important finding 
showing that patients may not be aware of  the severity 
of  their liver disease and may have developed significant 
levels of  fibrosis and cirrhosis before these are identified 
by treatment services.[11] It may also reflect the high levels 
of  other disease morbidities seen in this group along with 
symptoms of  drug and alcohol withdrawals that may mask 
symptoms of  chronic HCV infection. 
As expected, the patients with scores > 8.5 kPa were 
diagnosed with HCV significantly longer than those with a 
scores < 8.5 kPa (P=0.16). This reflects the progression of  
liver disease over time after HCV exposure.[10] Contrary to 
what might be expected, the impact of  self-declared drug 
and alcohol instability did not have a significant impact 
on fibroscan score. Ongoing alcohol misuse in chronically 
HCV infected individuals is associated with more severe 
liver disease.[10] Separating drug and alcohol stability as 
risks may have yielded a different result, but this finding is 
in keeping with poly-drug use pattern of  this cohort and 
the tendency to substitute alcohol and illicit drug use over 
a lifetime of  addiction and drug abuse. The high levels of  
self-declared drug and alcohol stability are also of  interest. 
Despite patients receiving therapeutic doses of  methadone 
maintenance treatment (MMT, average dose 75mL) for 
long periods of  time (>10 years) 70% indicated that drug /
alcohol instability affected their ability to engage with HCV 
services. This may reflect the level of  social exclusion (90% 
unemployment) of  this group and supports the provision 
of  augmented rehabilitation and support services to this 
marginalized group.
A unique finding of  this study was that with each unit 
increase in methadone dose, the odds of  being in the > 
8.5 Fibroscan group increased by 5.2%. To our knowledge, 
this has not been previously reported. This may indicate 
that the patients requiring higher doses of  methadone are 
at greater risk of  developing more severe liver disease and 
can potentially be used to target higher risk groups among 
PWIDs for HCV treatment interventions.   
Previous studies have illustrated how barriers to effective 
HCV care among Irish PWID center on negative 
experiences at diagnosis, investigations and treatment [35] 
Findings in this study described patient reluctance to 
engage with HCV assessment due to ongoing alcohol 
and drug use, injecting drug use, OST treatment relapse, 
fear around HCV and invasive treatment interventions 
and inability to attend due to custodial sentencing and 
lack of  prison referral.  Barriers to continued engagement 
centered on illness, distance from the treatment setting, 
early appointments and lack of  follow up appointments, 
potentially due to staff  concerns around on-going drug 
and alcohol use, or provided and not attended. Individual 
barriers to accessing HCV care reported elsewhere 
center on perceptions that HCV is a harmless disease 
or knowing someone who has died of  HCV, absence of  
symptoms, fear of  liver biopsy and standard treatment 
side effects (such as depression, fatigue, anxiety, anemia, 
fatigue, nausea, insomnia and flu like symptoms, and more 
rarely mania, psychosis and suicide), and the hospital 
setting with its logistical aspects, lengthy referral and 
waiting times, inflexible appointment systems and limited 
psychosocial supports.[14,21,36,54-56] Of  particular note were 
the significant barriers to treatment engagement reported 
by those with a fibroscan score of  > 8.5 kPa and eligible 
for DAA treatment, which centered on the inability to 
engage with HCV treatment and care due to custodial 
sentencing, parental bereavement, and chaotic family and 
drug using lifestyles. A majority of  participants in this 
study with fibroscan scores of  > 8.5 kPa were not aware 
of  HCV symptoms other than fatigue, and continued to 
struggle with drug and alcohol abuse. 
Structural factors affecting access relate to stigma, 
social and family support, housing, income, gender and 
criminalization.[15] The participants in this study had very 
high level of  unemployment (> 90%) and homelessness 
(40%) reflecting high levels of  social deprivation and 
barriers that need to be addressed to improve HCV 
treatment uptake. These challenges underpin the clear 
need to continually target PWID for HCV screening and 
treatment, particularly using non-invasive methods such as 
Fibroscanning and expand methadone treatment services 
to include housing and employment/training interventions 
within community drug treatment settings.  
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Willingness to start HCV treatment in PWID generally 
ranges between 53-86%.[29, 30, 32, 57] While this study did not 
include data on the numbers who subsequently engaged 
with HCV treatment, it does show that when HCV 
assessment services are provided locally in community drug 
treatment clinics, the patients are willing and able to engage. 
An 80% uptake of  fibro scan among this cohort is a very 
positive finding, particularly since over half  had previously 
been referred and attended one hospital appointment but 
failed to follow up for assessment and treatment. Providing 
on site HCV treatment with DAAs could further impact 
on treatment uptake.
Assessment facilitators include becoming symptomatic, 
knowing HCV infection can cause liver disease and desire 
to be treated for this virus.[21, 36] Modifiable barriers at 
this individual patient level include lack of  priority and 
knowledge, financial resources and fear of  side effects [21] 
Zickmund and colleagues,[58] in their study of  patients 
receiving opioid agonist therapy, described poor relations 
with health providers, lack of  access to health care and 
antiviral therapies as the central barriers occurring despite 
intense educational efforts. Patients in this study described 
negative structural aspects of  HCV services, which include 
lack of  follow-up appointments and early appointments 
difficult to attend to due to distances, and family issues. 
Studies elsewhere report that patient negative views are also 
strongly influenced by peer networks[21] and poor mental 
health.[54] Peer support groups are increasingly utilized to 
increase engagement in the HCV cascade of  care, and 
enhance patient knowledge.[59-60]
The barriers can be reduced by developing integrated 
care pathways, and incorporating HCV treatment and 
care within the community drug treatment services.[14, 15] 
Studies elsewhere emphasize the need to support and train 
nurses, general practitioners and addiction specialists in 
their key role in screening and PWID for HCV assessment 
and counselling.[14, 36] OST can underpin such HCV 
care pathways.[61] Findings from this study underpin the 
usefulness of  provision of  community fibroscanning in 
providing community-based treatment for “vulnerable 
populations” such as PWID with the new DAAs, and 
particularly when situated within drug treatment services. 
Afternoon clinics and enhanced prison referral systems 
are warranted.
The strengths of  this study include the selection of  a 
particularly hard to reach group of  HCV chronically 
infected PWIDs, a cohort that need to be studied to 
inform how HCV assessment and treatment uptake can 
be improved. It is the first study in Ireland to specifically 
target the chronically infected PWIDs and to identify their 
characteristics, to assess the extent of  liver disease, the 
numbers requiring treatment in accordance with present 
national HCV treatment guidelines and to explore patient 
identified barriers and enablers to HCV treatment. The 
single site location of  this study reduces it generalizability.
CONCLUSION
PWID are a high-risk and high-prevalence population 
for HCV infection.[12, 61] Although HCV treatment is 
effective for PWID,[21, 62] the uptake is lower than other risk 
groups.[29, 63-66] Offering HCV non-invasive fibroscanning 
within drug treatment services can identify and target 
those with chronic HCV, coupled with the potential 
positive outcomes when engaging in OST.  Self-declared 
HCV related symptoms are not a reliable indicator of  the 
level of  liver disease and outreach fibroscanning offers an 
ideal opportunity to identify patients with more advanced 
liver disease including cirrhosis that are eligible for DAAs. 
Similar barriers and enablers to HCV treatment were 
described by this Irish cohort of  PWID as previously 
described in previous studies, including drug and alcohol 
stability, injecting drug use, fear of  HCV treatment and liver 
biopsy, imprisonment, chaotic life style, social exclusion and 
stigma. Uniquely, this study found a link with methadone 
dose and higher fibroscan scores, a finding which requires 
further research. Findings are intended to inform HepCare 
Europe in their development of  a community based model 
of  care in order to engage with PWID who are affected 
and infected with HCV.
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